Results 161 to 170 of about 61,873 (283)

Exploring heart failure prevalence and dimensions: A comprehensive NT‐proBNP study in high‐risk primary care patients

open access: yesESC Heart Failure, EarlyView.
The diagnostic pathway of high‐risk primary care patients through NT‐proBNP. Abstract Introduction Early detection of heart failure (HF), particularly in asymptomatic individuals, is essential for timely intervention. This study aimed to determine the prevalence of HF among high‐risk individuals in primary care using N‐terminal probrain natriuretic ...
Ahmet Celik   +17 more
wiley   +1 more source

Effect of NT-proBNP on Serum Calcium: A Longitudinal Analysis. [PDF]

open access: yesMedicina (Kaunas)
Stancanelli MR   +12 more
europepmc   +1 more source

Identification of serum C4BPA as a potential diagnostic marker of right ventricular remodelling via proteomic analysis

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Right ventricular (RV) remodelling, a progressive condition characterized by maladaptive cardiac structural and functional changes, primarily results from prolonged pressure overload in patients with pulmonary hypertension (PH). Accurate, universal and easy‐to‐use biomarkers for assessing the severity of RV remodelling are lacking.
Xuenan Wang   +5 more
wiley   +1 more source

Increased plasma levels of N-terminal pro-B-type natriuretic peptide as biomarker for the diagnosis of cardioembolic ischaemic stroke

open access: yesNeurología (English Edition)
Background: Despite comprehensive study, the aetiology of stroke is not identified in 35% of cases. Aims: We conducted a study to assess the diagnostic capacity of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the identification of ischaemic ...
J.A. García-Carmona   +8 more
doaj  

Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence

open access: yesESC Heart Failure, EarlyView.
Abstract Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors represent one of the main cornerstones of heart failure treatment. Nevertheless, while the cardiovascular beneficial effects of these drugs have been clearly demonstrated by several clinical trials, in clinical practice, it remains challenging to identify the appropriate timing to start SGLT2 ...
Ruggero Mazzotta   +10 more
wiley   +1 more source

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper

open access: yesESC Heart Failure, EarlyView.
Abstract Background Sodium glucose co‐transporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists (MRA) reduce heart failure (HF) events in patients with heart failure and mildly reduced or preserved ejection fraction (HFmr/pEF). The randomized comparison of SGLT2i/MRA combination versus SGLT2i or MRA alone requires further testing in ...
João Pedro Ferreira   +26 more
wiley   +1 more source

Clinical significance of NT-proBNP as a predictive biomarker of depressive symptoms in cardiac patients. [PDF]

open access: yesFront Cardiovasc Med
Humayra S   +6 more
europepmc   +1 more source

Dapagliflozin effect on functional mitral regurgitation and myocardial remodelling: The DEFORM trial

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Functional mitral regurgitation (FMR) is associated with adverse outcomes in patients with heart failure, and current guideline‐directed medical therapy (GDMT) offers limited efficacy in managing FMR. This study aims to evaluate the therapeutic impact of the sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in patients with ...
Zhuoshan Huang   +18 more
wiley   +1 more source

The Role of NT-proBNP Levels in the Diagnosis of Hypertensive Heart Disease. [PDF]

open access: yesDiagnostics (Basel)
Mouzarou A   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy